Breakthrough REZOLVE-AD results position Rezpegaldesleukin as a potential first-in-class IL-2 Treg therapy for atopic dermatitis and asthma

In a development that may redefine the immunology landscape, Nektar Therapeutics (NASDAQ: NKTR) presented late-breaking Phase 2b data from the REZOLVE-AD study at the ACAAI 2025 Annual Scientific Meeting, showing that Rezpegaldesleukin (REZPEG) significantly improved both skin and respiratory outcomes in patients with moderate-to-severe atopic dermatitis. The IL-2 pathway agonist achieved robust efficacy not only on eczema severity and itch scores but also on asthma control parameters—an unusual and commercially significant dual-indication signal in dermatology.

How Rezpegaldesleukin demonstrated multi-dimensional efficacy across skin and respiratory outcomes in REZOLVE-AD

The REZOLVE-AD study enrolled 393 patients across 110 global sites, focusing on biologic- and JAK-inhibitor-naïve participants with moderate-to-severe atopic dermatitis. In this diverse cohort, Rezpegaldesleukin achieved statistically significant improvements across multiple endpoints. At the 24 µg/kg every-two-weeks dose, the therapy demonstrated meaningful gains in Eczema Area and Severity Index (EASI), Investigator Global Assessment (vIGA-AD 0/1), and ≥4-point reduction in itch NRS scores, all compared to placebo. The results achieved p-values of less than 0.05 to 0.001, depending on the endpoint, underscoring both the consistency and depth of clinical benefit.

Perhaps more striking were the exploratory findings in patients with asthma comorbidity, a subgroup representing roughly a quarter of the atopic dermatitis population. Among patients with baseline ACQ-5 ≥ 1.5—indicating uncontrolled asthma—Rezpegaldesleukin produced placebo-adjusted improvements ranging from 1.0 to 1.4 points, with 75 % of patients in the high-dose arm achieving at least a 0.5-point reduction, a threshold considered clinically meaningful in pulmonary research. The therapy’s impact on asthma control in a dermatologic study setting adds an unusual layer of translational relevance, hinting that the Treg-modulating mechanism may harmonize immune dysregulation across barrier and airway tissues.

Further evidence came from crossover data at Week 24, when placebo patients who switched to Rezpegaldesleukin achieved EASI-75 responses of 60 %, vIGA-AD 0/1 rates of 33 %, and itch reductions in half of the cohort. This progression implied that efficacy continues to deepen with sustained exposure—a promising indicator for long-term disease modification and real-world durability.

Why the IL-2 Treg mechanism positions Rezpegaldesleukin differently from existing biologics in atopic dermatitis

Rezpegaldesleukin works by selectively stimulating regulatory T cells through the IL-2 receptor complex, amplifying immune tolerance rather than broadly suppressing inflammation. This stands in sharp contrast to the dominant therapeutic classes in atopic dermatitis—namely IL-4/IL-13 antagonists like Dupixent from Sanofi and Regeneron, and JAK inhibitors such as Rinvoq from AbbVie and Cibinqo from Pfizer. While these drugs target inflammatory cytokines or their downstream signaling pathways, Rezpegaldesleukin aims to restore immunologic equilibrium upstream, effectively re-educating the immune system to self-regulate.

This approach could carry both scientific and commercial advantages. Because Treg modulation acts across multiple disease axes, the therapy might demonstrate broader organ-system benefits, as seen in the asthma subgroup data. Moreover, Treg-driven normalization could translate to longer remissions and reduced flare frequency after discontinuation—an outcome rarely achieved by cytokine blockers. For a chronic disease such as atopic dermatitis, which demands lifelong management, the appeal of a therapy that recalibrates rather than suppresses immunity could reshape market perceptions of what remission means.

Nektar’s scientific positioning around “immune balance rather than immune blockade” is also resonating with clinicians seeking gentler, longer-lasting solutions for young or systemically sensitive patients. If confirmed in Phase 3, Rezpegaldesleukin could occupy a unique therapeutic tier between biologics and immune-retraining agents, similar to how allergen immunotherapy shifted paradigms decades ago.

How Rezpegaldesleukin’s safety and durability profile compares with Dupixent and JAK inhibitors from AbbVie and Pfizer

Safety is where Nektar’s IL-2 platform could hold its strongest card. Early data show no meaningful safety imbalances versus placebo, with adverse events primarily mild to moderate and distributed evenly across treatment groups. No dose-related increases in infection, malignancy, or lab abnormalities were observed, contrasting with the boxed warnings that have shadowed JAK inhibitors for years.

When compared to Dupixent, Rezpegaldesleukin’s potential lies in differentiation rather than displacement. Dupixent, an entrenched market leader, delivers rapid skin clearance but often plateaus in itch relief and shows limited cross-organ benefits. Rezpegaldesleukin’s effect on both skin and airway function could extend its utility into broader “atopic syndrome” management, potentially capturing patients with multi-system involvement. If the Phase 3 data sustain its safety and dual-pathway efficacy, the drug might complement or even partially substitute existing biologics in refractory or comorbid populations.

In addition, durability is becoming a differentiating metric in the competitive atopic dermatitis market. While most biologics lose effect within weeks of discontinuation, Rezpegaldesleukin’s Treg-centric mode of action could yield longer-lasting immune recalibration. Although this remains speculative until long-term data mature, the concept of extended remission aligns well with the payer and patient preference for therapies that reduce chronic dosing dependence.

What the latest investor sentiment and stock performance reveal about Nektar Therapeutics after ACAAI 2025

Nektar Therapeutics’ stock (NASDAQ: NKTR) reacted positively following the ACAAI presentation, reflecting renewed confidence in the company’s IL-2 portfolio after several challenging years marked by prior partnership setbacks. Trading volume spiked over 250 % on the first trading day after the conference, and NKTR shares gained nearly 18 % week-over-week, reversing a multi-month downtrend that had kept the stock below $1.50 since mid-summer. Analysts noted that the REZOLVE-AD dataset marks the company’s most complete and clinically persuasive evidence since 2019, when its earlier IL-2 programs failed to meet endpoints in oncology.

Institutional sentiment has shifted accordingly. Several small-cap biotech funds that had exited the position in 2023 reportedly re-entered after the ACAAI event, citing “clearer biomarker translation and cross-indication optionality.” Retail interest also rose, supported by coverage across immunology and dermatology investor channels highlighting the “dual-benefit story.”

Still, the road ahead remains demanding. Investors are cautious about capital requirements for Phase 3 trials, which could exceed $150 million. Nektar’s management has indicated ongoing strategic discussions with potential partners, and the strong REZOLVE-AD signal is expected to strengthen those negotiations. If a partnership or co-development deal materializes in early 2026, it could provide both funding security and validation.

How upcoming milestones and regulatory timelines could shape Rezpegaldesleukin’s Phase 3 and market trajectory through 2026

Nektar has signaled plans to initiate global Phase 3 trials in the first half of 2026 using the 24 µg/kg every-two-weeks regimen, supported by a 24-week induction design. The company expects 52-week maintenance data from REZOLVE-AD in Q1 2026, which will guide dosing and trial structure. In parallel, top-line results from the REZOLVE-AA study for alopecia areata are due in December 2025, offering another opportunity to validate the same Treg-based mechanism in a second autoimmune condition.

Regulatory strategy discussions with the U.S. Food and Drug Administration are anticipated following the completion of the 52-week dataset. Given the broad mechanistic novelty and observed asthma benefit, analysts suggest Nektar may pursue an expanded clinical development path encompassing combined skin-airway indications, potentially with Fast Track or Breakthrough Therapy status.

The competitive environment will also evolve rapidly. Sanofi and Regeneron are advancing Dupixent into chronic obstructive pulmonary disease (COPD) and prurigo nodularis, while AbbVie and Pfizer are refining topical and oral JAK programs to improve tolerability. Against that backdrop, Rezpegaldesleukin’s differentiating biology—leveraging immune regulation instead of inhibition—could carve out a distinct niche and attract multi-indication investment attention.

From a commercial standpoint, market analysts estimate that even a modest capture of 10 % of the moderate-to-severe atopic dermatitis population could generate over $1.5 billion in annual global sales. If asthma label expansion becomes viable, the market potential would likely exceed $3 billion. For a company with a current market capitalization below $400 million, those projections represent an asymmetrical upside scenario contingent on execution and regulatory success.

What the broader implications of the REZOLVE-AD findings suggest for immune modulation and market leadership in atopic disease

The REZOLVE-AD data do more than strengthen Nektar’s narrative—they may also reignite industry confidence in IL-2 pathway engineering, a field that had cooled after earlier oncology disappointments. By demonstrating that precise IL-2 tuning can restore regulatory function without triggering hyperactivation, Rezpegaldesleukin reopens the conversation on immune recalibration as a therapeutic strategy. For dermatology, this could mark the start of a transition from symptom control to immune correction.

If future results maintain their momentum, Rezpegaldesleukin could become the first clinically validated Treg-modulating agent in atopic disease. That achievement would not only diversify Nektar’s pipeline beyond oncology but also influence the broader biopharma landscape, inviting renewed competition in selective IL-2 and Treg biology. With the Phase 3 program approaching and new partnership prospects emerging, the coming year will likely determine whether this once-underestimated biotech reclaims its position as a frontrunner in immune modulation.